The Ministry of Health has registered a vaccine against COVID-19 of the FMBA "Konvasel" center

The vaccine is a subunit recombinant vaccine administered intramuscularly. Its shelf life is six months

The Russian Ministry of HEALTH has registered the Konvasel CORONAVIRUS vaccine developed by the St. Petersburg Research Institute of Vaccines and Serums of the Federal Medical and Biological Agency (FMBA) of RUSSIA, follows from the register of the ministry.

Convasel is a subunit recombinant vaccine for the prevention of coronavirus infection caused by the SARS-CoV-2 virus. Date of decision: 03/18/2022, ”is indicated in the register.

According to information on the website of the Ministry of Health, the vaccine has a shelf life of six months under the following storage conditions - a temperature of two to eight degrees in a place protected from light.

Gunzburg Reveals Details About New Vaccine With Virus-Like Particles Society

FMBA submitted an application to the Ministry of Health for registration of the Convasel vaccine on January 21. Prior to this, on December 31 last year, the HEAD of the FMBA, Veronika Skvortsova, said that the vaccine could be registered before the end of the first quarter of 2022. According to her, in June 2021, preclinical studies of the drug were completed, as a result of which its safety, immunogenicity and protective potential were proven.

Read together with it: